Corcept Resubmits FDA Application for Relacorilant in Cushing’s
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Corcept Therapeutics ( (CORT) ) has shared an announcement.
On June 17, 2026, Corcept Therapeutics said it had resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome, following an agency request for additional analyses of data from its original filing. The company said it expects a six‑month review, with the package supported by positive results from the pivotal GRACE trial, the Phase III GRADIENT trial, a long‑term extension study and earlier‑stage data indicating durable symptom improvement with a potentially more favorable safety profile than existing therapies.
The resubmission marks a key regulatory step in Corcept’s effort to expand relacorilant beyond its existing use in ovarian cancer and could strengthen its position in the hypercortisolism market, where it already sells Korlym. For patients with Cushing’s syndrome, the filing reflects progress toward another targeted medical option in a condition that can be fatal if inadequately treated and is now believed to be more common than previously recognized.
The most recent analyst rating on (CORT) stock is a Buy
with a $95.00 price target.
To see the full list of analyst forecasts on Corcept Therapeutics stock,
see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
The score is driven by strong financial resilience (notably the very low-debt balance sheet and solid cash generation) and a favorable earnings-call outlook with raised revenue guidance and significant clinical/regulatory momentum. These positives are partially offset by elevated valuation (very high P/E), recent profitability compression, and technically overbought conditions that increase near-term volatility risk.
To see Spark’s full report on CORT stock,
click here.
More about Corcept Therapeutics
Corcept Therapeutics, based in Redwood City, Calif., is a commercial-stage biopharmaceutical company focused on discovering and developing medications that modulate the effects of the hormone cortisol to treat severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a selective glucocorticoid receptor antagonist approved in 2026 in combination with nab-paclitaxel for adults with platinum-resistant ovarian cancer, and is running advanced clinical trials across Cushing’s syndrome, solid tumors, ALS and liver disease.
Corcept’s portfolio centers on proprietary selective cortisol modulators and glucocorticoid receptor antagonists, including relacorilant, which has orphan drug status in the U.S. and Europe for hypercortisolism and in Europe for ovarian cancer. The company holds composition of matter, method of use and other patents covering relacorilant and related molecules, underlining its strategy to build a defensible franchise in cortisol modulation across multiple serious diseases.
Average Trading Volume: 1,403,199
Technical Sentiment Signal: Buy
Current Market Cap: $8.92B
For an in-depth examination of CORT stock, go to TipRanks’ Overview page.
